* Indian authorities issue first compulsory license * Drugmakers target India growth, but wary of patent regulations * HIV/AIDS, heart disease treatments targeted by campaigners (Adds link, smends headline) By Kaustubh Kulkarni and Henry Foy MUMBAI, March 13 (Reuters) - India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say.